Glaucoma News and Research

Latest Glaucoma News and Research

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Incidence of childhood myopia has more than doubled over last 50 years among American children

Incidence of childhood myopia has more than doubled over last 50 years among American children

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Three new genetic associations identified for primary open angle glaucoma

Three new genetic associations identified for primary open angle glaucoma

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

Head-down yoga positions fatal for glaucoma patients

Head-down yoga positions fatal for glaucoma patients

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

BioLight announces first sale of IOPtiMate system in Portugal

BioLight announces first sale of IOPtiMate system in Portugal

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

Johns Hopkins researchers develop method to turn stem cells into retinal ganglion cells

Johns Hopkins researchers develop method to turn stem cells into retinal ganglion cells

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight signs joint financing agreement with two Asia-based venture capital firms

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

AAO recognizes outstanding eye physicians and surgeons for innovation in patient care

AAO recognizes outstanding eye physicians and surgeons for innovation in patient care

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Saint Louis University ophthalmologist offers tips to manage night vision issues

Saint Louis University ophthalmologist offers tips to manage night vision issues

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.